etaracizumab   Click here for help

GtoPdb Ligand ID: 6596

Synonyms: etaratuzumab | hLM60 | MEDI-522
Compound class: Antibody
Comment: Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Etaracizumab is a humanized investigational monoclonal antibody for the treatment of metastatic melanoma, prostate cancer, ovarian cancer and various other types of cancer [1]. Click here to view records held with ClinicalTrials.gov which are assessing this antibody.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Etaracizumab targets integrin αVβ3 (vitronectin receptor) [3]. Vitronectin is a serum and extracellular matrix glycoprotein involved in cell adhesion and migration, and may be involved in tumour malignancy [2]. Interaction between vitronectin and integrin αVβ3 anchors cells to the extracellular matrix. Etaracizumab inhibits this interaction and has antitumor, antiangiogenic, and antiosteolytic activities [3].